Post-marketing Clinical Study of Irbesartan <Evaluation of safety and efficacy of long-term administration>
Phase 4
- Conditions
- essential hypertension
- Registration Number
- JPRN-jRCT1080220722
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients whose trough seated blood pressure at the end of washout period >= 160/90 mmHg or >= 150/95 mmHg
Exclusion Criteria
Patients with renal, hepatic or heart disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events and adverse drug reactions, etc.
- Secondary Outcome Measures
Name Time Method Change from baseline in trough seated diastolic blood pressure, etc.